 RESEARCH TRIANGLE PARK, N.C., April 30, 2021 GLOBE NEWSWIRE -- BioCryst Pharmaceuticals, Inc. Nasdaq: BCRX today announced that the European Commission EC has approved oral, once-daily ORLADEYOTM berotralstat for the prevention of recurrent hereditary angioedema HAE attacks in HAE patients 12 years and older. 